Results expression for tests used to measure the anticoagulant effect of new oral anticoagulants

Thrombosis Journal

Volumn 11, Issue 1, 2013, Pages

  Tripodi, Armando ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; DABIGATRAN; ECARIN; RIVAROXABAN; THROMBIN; THROMBOPLASTIN;

ANTICOAGULATION; BLOOD CLOTTING TIME; HUMAN; INTERNATIONAL NORMALIZED RATIO; PROTHROMBIN TIME; REVIEW;

EID: 84879434874     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-11-9     Document Type: Review

References (18)

1. Tripodi A, Palareti G. New Anticoagulant Drugs for Treatment of Venous Thromboembolism and Stroke Prevention in Atrial Fibrillation. J Intern Med 2012, 271:554-565.
2. Pengo V, Crippa L, Falanga A, et al. Italian Federation of Thrombosis Centers. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. Consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011, 106:868-876.
3. Baglin T, Hillarp A, Tripodi A, et al. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013, 11:756-760.
4. van den Besselaar AMHP, Poller L, Tripodi A. World Health Organization (WHO) Guidelines for thromboplastins and plasma used to control oral anticoagulant therapy 1999, 64-93. WHO Technical Report, Volume Series, No. 889.
5. Tripodi A, Chantarangkul V, Primignani M, Fabris F, Dell'Era A, Sei C, Mannucci PM. The international normalized ratio calibrated for cirrhosis (inrliver) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007, 46:520-527.
6. Kim HK, Hong KH, Toh CH, On behalf of the Scientific and Standardization Committee on DIC of the International Society on Thrombosis and Haemostasis (ISTH) Application of the International Normalized Ratio (INR) in the Scoring System for Disseminated Intravascular Coagulation (DIC). J Thromb Haemost 2010, 8:1116-1118. On behalf of the Scientific and Standardization Committee on DIC of the International Society on Thrombosis and Haemostasis (ISTH).
7. Tripodi A, Chantarangkul V, Clerici M, Palmucci C, Bison E, Banzato A, Biguzzi E, Pengo V. Standardization of Lupus Anticoagulant. Feasibility Study of a Calibration Model to Minimize Between-method Variability. Thromb Res 2011, 127:589-594.
8. Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010, 103:815-825.
9. Tripodi A, Chantarangkul V, Guinet C, et al. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost 2011, 9:226-228.
10. Harenberg J, Marx S, Krämer R, Giese C, Weiss C. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. Blood Coagul Fibrinolysis 2011, 22:637-641.
11. van den Besselaar AMHP, Barrowcliffe TW, Houbouyan-Réveillard LL, Jespersen J, Johnston M, Poller L, Tripodi A, On behalf of the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the ISTH Guidelines on preparation, certification and use of certified plasmas for ISI calibration and INR determination. J Thromb Haemost 2004, 2:1946-1953. On behalf of the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the ISTH.
12. Samama MM, Contant G, Spiro TE, Perzborn E, Flem LL, Guinet C, Gourmelin Y, Martinoli JL. Rivaroxaban Prothrombin Time Field Trial Laboratories. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost 2012, 18:150-158.
13. Samama MM, Amiral J, Guinet C, et al. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost 2010, 104:1078-1079.
14. Samama MM, Contant G, Spiro TE, , et al. for the Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012, 107:379-387. for the Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories.
15. Kitchen S, Iampietro R, Woolley AM, Preston FE. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost 1999, 82:1289-1293.
16. Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost 1996, 22:197-202.
17. Stangier J, Rathgen K, Staehle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Brit J Clin Pharmacol 2007, 64:292-303.
18. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012, 23:138-143.